RU2003104798A - Содержащие циланзетрон лекарственные средства для лечения не страдающих запорами пациентов мужского пола с синдромом раздраженного кишечника (срк) - Google Patents

Содержащие циланзетрон лекарственные средства для лечения не страдающих запорами пациентов мужского пола с синдромом раздраженного кишечника (срк) Download PDF

Info

Publication number
RU2003104798A
RU2003104798A RU2003104798/15A RU2003104798A RU2003104798A RU 2003104798 A RU2003104798 A RU 2003104798A RU 2003104798/15 A RU2003104798/15 A RU 2003104798/15A RU 2003104798 A RU2003104798 A RU 2003104798A RU 2003104798 A RU2003104798 A RU 2003104798A
Authority
RU
Russia
Prior art keywords
use according
ibs
treatment
irrital
cylanesetron
Prior art date
Application number
RU2003104798/15A
Other languages
English (en)
Inventor
Вернер КАУТРЕЛС (NL)
Вернер КАУТРЕЛС
Клаус Рудольф ШТАЙНБОРН (DE)
Клаус Рудольф Штайнборн
Хайнц Гюнтер КРАУЗЕ (DE)
Хайнц Гюнтер КРАУЗЕ
Стивен Дейвид КАРАС (US)
Стивен Дейвид КАРАС
Эгбертус Хендрикус Эверт БИШЁВЕЛ (NL)
Эгбертус Хендрикус Эверт БИШЁВЕЛ
Албертус Германнус Дирк ПЛЕККЕНПОЛ (NL)
Албертус Германнус Дирк ПЛЕККЕНПОЛ
Original Assignee
Зольвай Фармасьютиклз Гмбх (De)
Зольвай Фармасьютиклз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10123447A external-priority patent/DE10123447A1/de
Application filed by Зольвай Фармасьютиклз Гмбх (De), Зольвай Фармасьютиклз Гмбх filed Critical Зольвай Фармасьютиклз Гмбх (De)
Publication of RU2003104798A publication Critical patent/RU2003104798A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (8)

1. Применение циланзетрона или его фармакологически приемлемых кислотно-аддитивных солей и/или сольватов для получения фармацевтических композиций, предназначенных для лечения и/или профилактики синдрома раздраженного кишечника (СРК) у не страдающих запорами пациентов мужского пола.
2. Применение по п.1, при котором используют гидрохлорид циланзетрона.
3. Применение по п.1, при котором используют моногидрат гидрохлорида циланзетрона.
4. Применение по меньшей мере одного антагониста 5НТ3-рецептора для получения фармацевтической композиции, предназначенной для лечения страдающих синдромом раздраженного кишечника пациентов обоего пола при ее приеме трижды в день.
5. Применение по п.4, при котором по меньшей мере один антагонист 5НТ3-рецептора применяют в дозе от 1 до 16 мг.
6. Применение по п.4, при котором препарат принимают трижды в день после основных приемов пищи утром, в дневное время и вечером соответственно.
7. Применение по п.4, при котором в качестве антагониста 5НТ3-рецептора применяют алозетрон, азазетрон, долазетрон, гранизетрон, индизетрон, итазетрон, леризетрон, онданзетрон, рамозетрон, тропизетрон и/или (R)-закоприд.
8. Применение по п.4, при котором в качестве антагониста 5НТ3-рецептора применяют циланзетрон или его фармакологически приемлемые кислотно-аддитивные соли и/или сольваты.
RU2003104798/15A 2000-07-26 2001-07-18 Содержащие циланзетрон лекарственные средства для лечения не страдающих запорами пациентов мужского пола с синдромом раздраженного кишечника (срк) RU2003104798A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10036645 2000-07-26
DE10036645.7 2000-07-26
DE10123447.3 2001-05-14
DE10123447A DE10123447A1 (de) 2000-07-26 2001-05-14 Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten

Publications (1)

Publication Number Publication Date
RU2003104798A true RU2003104798A (ru) 2004-06-27

Family

ID=26006529

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003104798/15A RU2003104798A (ru) 2000-07-26 2001-07-18 Содержащие циланзетрон лекарственные средства для лечения не страдающих запорами пациентов мужского пола с синдромом раздраженного кишечника (срк)

Country Status (16)

Country Link
EP (1) EP1307195A2 (ru)
JP (1) JP2004504343A (ru)
CN (1) CN1444479A (ru)
AR (1) AR028970A1 (ru)
AU (1) AU2001276409A1 (ru)
BR (1) BR0112690A (ru)
CA (1) CA2417677A1 (ru)
CZ (1) CZ2003158A3 (ru)
HU (1) HUP0301479A2 (ru)
IL (1) IL153972A0 (ru)
MX (1) MXPA02012917A (ru)
NO (1) NO20030373L (ru)
PL (1) PL363517A1 (ru)
RU (1) RU2003104798A (ru)
SK (1) SK1272003A3 (ru)
WO (1) WO2002007713A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
WO2005072730A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. 下痢型過敏性腸症候群治療剤
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
HUP0301479A2 (hu) 2003-09-29
SK1272003A3 (en) 2003-07-01
CN1444479A (zh) 2003-09-24
JP2004504343A (ja) 2004-02-12
WO2002007713A3 (de) 2002-11-14
CA2417677A1 (en) 2003-01-27
IL153972A0 (en) 2003-07-31
NO20030373D0 (no) 2003-01-24
AR028970A1 (es) 2003-05-28
MXPA02012917A (es) 2003-05-14
WO2002007713A2 (de) 2002-01-31
BR0112690A (pt) 2003-06-24
CZ2003158A3 (cs) 2003-08-13
NO20030373L (no) 2003-01-24
AU2001276409A1 (en) 2002-02-05
PL363517A1 (en) 2004-11-29
EP1307195A2 (de) 2003-05-07

Similar Documents

Publication Publication Date Title
US20020107236A1 (en) Methods of treating sexual dysfunction associated with hypertension
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
JP2009536176A5 (ru)
RU2010123027A (ru) Фармацевтические композиции двойного действия на основе надмолекулярных структур антагониста/блокатора рецепторов ангиотензина (arb) и ингибитора нейтральной эндопептидазы (nep)
DK1487461T3 (da) Fremgangsmåder til anvendelse af og præparater omfattende immunomodulatoriske forbindelser til behandling og håndtering af myelodysplastiske syndromer
ATE427740T1 (de) Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
WO2005118579A3 (en) Thiazole derivatives as chemokine receptor antagonists
WO2014142607A1 (ko) 약제학적 복합제제
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
McInnes et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
US20160263040A1 (en) Composite formulation comprising tadalafil and amlodipine
RU2002105377A (ru) Ксенон-антагонист nmda
RU2003104798A (ru) Содержащие циланзетрон лекарственные средства для лечения не страдающих запорами пациентов мужского пола с синдромом раздраженного кишечника (срк)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
WO2008005352A3 (en) Solid dose formulations of a thrombin receptor antagonist
US10864191B2 (en) 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
US20030125349A1 (en) Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
WO2001041535A3 (en) Eplerenone crystalline form
KR20090065510A (ko) 올메사탄 메독소밀 및 암로디핀의 고형 투여 제형
Trailokya Will Azilsartan-An eight ARB bring paradigm shift in hypertension management practices in India
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
MXPA03001210A (es) Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
CA2516433A1 (en) Ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20050111